BIO


Lazard

Banc of America Securities


CIBC World Markets

Pacific Growth Equities

citigroup

Printable Version

Program subject to change. All events take place at the Palace Hotel unless otherwise noted.
 
Tuesday, October 12, 2004
4:00 PM – 7:00 PM Registration (Sonoma Room, Second Floor)
6:00 PM - 8:00 PM Opening Reception - Garden Court, Palace Hotel
 
Wednesday, October 13, 2004
7:00AM – 5:00 PM Registration (Sonoma Room, Second Floor)
7:15 AM – 9:30 AM Breakfast
7:50 AM – 9:30 AM Plenary Session

The Emerging Finance Model for Biotech
 Welcome: Carl B. Feldbaum, President, Biotechnology Industry Organization
Moderator: Andrew J. Weisenfeld, Managing Director, Banc of America Securities
Sponsor: Heller Ehrman
8:00 AM – 6:00 PM One-on-One Meetings
9:30 AM – 10:30 AM Workshops and Roundtables
•     Novel Cardiovascular Drugs from the Biotechnology Industry
•     Business Strategies in the Era of Personalized Medicine
•     The Future of Biotech M&A
•     Why Should VCs Invest in Early Stage Companies?
10:30 AM – 12:30 PM Company Presentations
12:30 PM – 2:00 PM

Luncheon with Keynote Speaker

Keynote:  Margaret A. Tempero, MD, Chief, Medical Oncology, Department of Medicine, University of California, San Francisco; Past President, American Society of Clinical Oncology (ASCO) (2003-04) 
Hosts: Lazard & Banc of America Securities
2:00 PM – 4:00 PM Company Presentations
4:00 PM – 5:00 PM Workshops and Roundtables
•     What a Pain:  Clinical and Mechanistic Insights into the Underlying Physiology and Treatment of Neuropathic Pain
•     Managing AIDS for Long Term Survival: Treatments on the Horizon
•     The Future of Obesity Therapy: Diet? Drugs? Devices?
•     Topping off the Tank: Everything You Wanted to Ask About Late Stage, Mezzanine and Crossover Financing
•     The Drug Hunter's Secrets
6:30 PM – 9:00 PM Gala Reception -  Asian Art Museum

Hosts: Lazard & Banc of America Securities
Co-Hosts: CIBC World Markets, Pacific Growth Equities & Citigroup
Sponsors: Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Chiron Corporation, Gilead, Johnson & Johnson, Merck
 
Thursday, October 14, 2004
7:00 AM – 5:00 PM Registration (Sonoma Room, Second Floor)
7:15 AM – 9:30 AM Breakfast
7:50 AM – 9:30 AM Plenary Session

Operating in a New Reimbursement Environment
Welcome: Morrie Ruffin, Vice President, Business Development & Emerging Companies, Biotechnology Industry Organization
Moderator: David Low, Partner, Lazard
Host: Gilead
8:00 AM –  6:00 PM One-on-One Meetings
9:30 AM – 10:30 AM Workshops and Roundtables
•     Cancer Trial Endpoints: The Bar Keeps Moving
•     Horn of Plenty: Clinical Development Strategies for Drug Candidates With Multiple Indications
•     It's All About Chemistry: The View From the Top on Creating Pharma-Quality Drugs
•     Leading Edge Developments in the Treatment of Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis
•     Specialty Pharmaceutical Business Strategies
10:30 AM – 12:30 PM Company Presentations
12:30 PM – 2:00 PM Luncheon with Keynote Speaker

Keynote:  Gregory T. Lucier, Chairman & CEO, Invitrogen Corporation 
Hosts: CIBC World Markets, Pacific Growth Equities & Citigroup
2:00 PM – 4:00 PM Company Presentations
4:00 PM – 5:00 PM Workshops and Roundtables
•     Stopping Neurodegenerative Disease in its Tracks
•     Standing at the Crossroads of Cancer and Autoimmunity
•     The Re-Emergence of the Drug Discovery Model
•     Proof of Concept and Beyond: Setting Up for a Successful Phase III
•     Partnering Structures: The Good, the Bad and the Ugly
5:30 PM – 7:30 PM Offsite Receptions
 
Friday, October 15, 2004
7:00 AM – 12:00 PM Registration (Sonoma Room, Second Floor)
7:30 AM – 9:00 AM Breakfast
8:00 AM – 2:00 PM One-on-One Meetings
8:30 AM – 9:30 AM Workshops and Roundtables
•     Strategies in Early Clinical Development of Biologic Agents in Autoimmune Disease
•     Beyond Crystal Balls: Using Preclinical Testing Technologies to Enhance the Drug Development Cycle
•     Zeroing in on Cancer Therapies: Updates on Targets and Programs
• Everything You Want to Know About the Buyside - Past, Present & Future
•     SNPs & Snippets: Applications for Drug Discovery, Clinical Trials and Treatment
9:30 AM – 12:30 PM Company Presentations
12:30 PM – 2:00 PM Closing Luncheon and Plenary Session

Choosing an Investment Bank for Your IPO and Positioning Your Company for Long Term Access to Capital Markets 
Moderator: Alan Mendelson, Partner, Latham & Watkins
Sponsor: Ernst & Young